—Risk stratification in follicular lymphoma relies on clinical parameters, lab tests, and histology to determine which patients should receive early treatment. Genetic tests may soon be added to ...

In the future, the incorporation of circulating tumor DNA (ctDNA) could help to further risk-stratify patients, Alderuccio added. "Follicular lymphoma is very heterogenous, and ctDNA may capture ...

Alderuccio noted that the treatment landscape for high-risk follicular lymphoma has changed dramatically just in the last few years. Patients now have many more treatment options than they once did.